In conclusion, to our knowledge, this is the first study in China to set a model to predict the prognosis of NSCLC patients treated with anti-PD-1/PD-L1 plus bevacizumab, which provides a useful basis for the treatment of NSCLC patients. Here, PDCD1 is linked to non-small cell lung carcinoma.